image-guided radiation therapy

RADIATION15 trials

Sponsors

National Institutes of Health Clinical Center (CC), Mayo Clinic, Centre Antoine Lacassagne, Cancer Trials Ireland, The Netherlands Cancer Institute

Conditions

Adenocarcinoma of the LungAdenocarcinoma of the ProstateAdenosquamous Cell Lung CancerBladder CancerBreast CancerCancer of Head and NeckCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell of Head and Neck

Phase 1

Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer

CompletedNCT00653757

Mayo ClinicProstate Cancer

Start: 2002-03-31End: 2007-12-31Target: 100Updated: 2012-03-19

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

CompletedNCT00872625

Centre Antoine LacassagneBreast Cancer

Start: 2007-04-30End: 2010-12-31Updated: 2025-09-30

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

CompletedNCT01028885

Abramson Cancer Center at Penn MedicineAdenocarcinoma of the Prostate, Prostate Cancer, Stage III Prostate Cancer +2

Start: 2009-06-30End: 2018-06-30Target: 10Updated: 2019-07-25

3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder

Institute of Cancer Research, United KingdomBladder Cancer

Start: 2009-05-31Target: 60Updated: 2013-08-26

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

CompletedNCT04879849

TakedaCarcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms

Start: 2021-09-09End: 2024-04-30Updated: 2025-09-04

Phase 2

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

TerminatedNCT00550654

National Institutes of Health Clinical Center (CC)Kidney Cancer, Melanoma (Skin), Metastatic Cancer +3

Start: 2007-10-31End: 2010-05-31Updated: 2017-01-13

Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer

CompletedNCT00714753

Mayo ClinicProstate Cancer

Start: 2008-08-31End: 2013-12-31Updated: 2019-08-07

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

Cancer Trials IrelandProstate Cancer

Start: 2009-07-20End: 2025-10-31Updated: 2023-04-06

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

WithdrawnNCT01859689

Jonsson Comprehensive Cancer CenterAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIA Prostate Cancer +2

Start: 2012-03-31End: 2013-09-30Updated: 2020-07-27

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

CompletedNCT02296684

Washington University School of MedicineCancer of Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer +3

Start: 2015-03-25End: 2025-07-21Updated: 2026-01-15

Unknown Phase

Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer

CompletedNCT01024582

The Netherlands Cancer InstituteBreast Cancer

Start: 2009-10-31End: 2017-02-28Updated: 2017-09-27

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Active, not recruitingNCT01345851

Jonsson Comprehensive Cancer CenterAdenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer +6

Start: 2011-03-23End: 2028-01-31Updated: 2026-02-25

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

CompletedNCT02186470

Ohio State University Comprehensive Cancer CenterEstrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component +7

Start: 2016-04-29End: 2025-09-04Updated: 2025-09-22

Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)

CompletedNCT03176173

Stanford UniversityStage IV Non-Small Cell Lung Cancer

Start: 2017-06-28End: 2025-01-31Updated: 2025-11-05

Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy

CompletedNCT03623334

University of Texas Southwestern Medical CenterNon-small Cell Lung Cancer

Start: 2009-10-05End: 2018-02-10Updated: 2021-05-04

Related Papers

Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients.

2026-04-01

Data from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025-12-31

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

2025-12-01

5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multi-center, two-cohort, phase 2 trial.

Journal of Clinical Oncology2025-05-28

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

Nature Communications2025-05-178 citations

Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study

International Journal of Radiation Oncology*Biology*Physics2024-07-273 citations

Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer

JAMA Oncology2024-01-1117 citations

Abstract PO-002: Pembrolizumab as neoadjuvant and adjuvant therapy in combination with standard of care in resectable, locally advanced head and neck squamous cell carcinoma: Phase 3 KEYNOTE-689

Clinical Cancer Research2023-09-154 citations

Abstract PO-078: Tissue-resident memory CD8+ T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance

Clinical Cancer Research2023-09-15

Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

Science Immunology2023-09-08100 citations

CANTO-RT: One of the Largest Prospective Multicenter Cohort of Early Breast Cancer Patients Treated with Radiotherapy including Full DICOM RT Data

Cancers2023-01-2512 citations

503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma

Regular and Young Investigator Award Abstracts2022-11-012 citations

529 Reduced dendritic cell infiltration in anti-PD-1 resistant head and neck squamous cell carcinoma

Regular and Young Investigator Award Abstracts2022-11-01

Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors

Cancer Research2022-06-157 citations

Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models

Cancer Research2022-06-153 citations

Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN)

Cancer Research2022-06-152 citations

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-0118 citations

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.

Journal of Clinical Oncology2022-06-0117 citations

Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study – a phase I/II clinical trial protocol

BMC Cancer2022-04-0217 citations

Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2021-05-2038 citations

11 more papers not shown